UK Medicines Information
Teprotumumab for Thyroid-Associated Ophthalmopathy
Information type:
Randomised controlled trials
Source:
New England Journal of Medicine
Specialities:
Endocrine system disorders | Eyes and vision
Summary
This RCT (n=87) reports 69% of patients who received teprotumumab vs 20% who received placebo had a clinical response (defined as a reduction of 2 points or more in the Clinical Activity Score and a reduction of 2 mm or more in proptosis at week 24 (P<0.001).
UKMi comment
Teprotumumab is a fully human insulin-like growth factor I receptor inhibitory monoclonal antibody.
Related links: